Bitcoin sets a new all-time high above $6,000 >>> READ MORE

Flu Season Is Coming — And These Companies Are Ready

As folks get the flu, several publicly traded companies benefit

      View All  

Flu Vaccines

While the CDC hasn’t been able to analyze the circulating virus yet, there’s not much we can do about it. So the best course of action for now is to get a flu shot — especially while it’s still early in flu season.

Novartis (NVS), to start, had a scare last October with its flu vaccine, but it’s still one of the world’s top vaccine producers, boasting Agrippal, Fluad, Flucelvax and Fluvirin.

French pharmaceutical company Sanofi (SNY) also makes several vaccines — including Fluzone, Intanza, Panenza and Vaxigrip. In fact, Fluzone High-Dose was recently shown to offer 24% better protection than the regular formula in patients 65 and older, and research firm Global Data said Sanofi’s Fluzone franchise of influenza vaccine products “is expected to help position the multinational vaccine manufacturer as a formidable player in the U.S. market.”

Meanwhile, GlaxoSmithKline (GSK) manufactures Fluarix and FluLaval, and companies such as Merck (MRK) and AstraZeneca (AZN) get in on the action through subsidiaries, as InvestorPlace contributor James Brumley explained last flu season.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC